AngioDynamics, Inc. (ANGO)

Over the past six months, AngioDynamics' stock has been influenced by several events. The company reported strong Q1 and Q2 fiscal year 2026 earnings, leading to raised FY2026 guidance. Insider trading occurred in October 2025 with purchases by executives. AngioDynamics presented at the UBS Global Healthcare Conference in November 2025. Analyst ratings were updated, with Canaccord Genuity reiterating a "Buy" rating. Strategic overhaul involved divesting slow-growing businesses to focus on high-growth MedTech platforms. The stock's 52-week range has been between $8.27 and $13.99, and analysts have a consensus "Moderate Buy" rating with an average twelve-month price objective of $19.33.

While specific seasonal fluctuations are not detailed, demand for AngioDynamics' products is primarily driven by the rising global demand for minimally invasive therapies, clinical validation, and regulatory progress. The Med Tech segment is experiencing substantial growth, expanding its customer base. International expansion and operational cost savings initiatives are also expected to contribute to sustained growth.

AngioDynamics, Inc. is a medical technology company based in Latham, New York, that designs, manufactures, and sells medical, surgical, and diagnostic devices. The company operates within the Healthcare sector, focusing on vascular access, peripheral vascular intervention, and interventional oncology. The Med Tech segment includes the Auryon Atherectomy system, thrombus management platform, and NanoKnife IRE Ablation System. The Med Device segment focuses on core, venous, ports, and other oncology products, including implanted ports, PICCs, hemodialysis catheters, and angioplasty balloons.

AngioDynamics primarily generates revenue from the United States, but also sells its medical devices internationally.

AngioDynamics' brand reputation has seen positive developments recently. The NanoKnife System was named to TIME's 2025 Best Inventions List. The company achieved clinical milestones with patient enrollments in the AMBITION BTK and RECOVER-AV trials. Analysts have a generally positive outlook, with a "Strong Buy" consensus rating.

AngioDynamics' stock is owned by a mix of institutional, retail, and individual investors. Approximately 29.32% of the company's stock is owned by institutional investors, with major shareholders including Divisadero Street Capital Management, LP, BlackRock, Inc., Systematic Financial Management Lp, Point72 Asset Management, L.P., and The Vanguard Group, Inc. Insiders own about 5.36% of the company's stock, with the CEO, James Clemmer, holding 1.2% of the total shares outstanding. Public companies and individual investors collectively own approximately 65.32% of the stock, with individual investors holding a 17% stake.